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Background
Involvement of the heart drives prognosis in Systemic
AL Amyloidosis, predicting outcome and influencing
therapeutic options. Current methods of cardiac assess-
ment do not allow formal quantification of the amyloid
load. We used Equilibrium Contrast Cardiovascular
Magnetic Resonance (EQ-CMR) to measure the intersti-
tial compartment of the heart by measuring the myocar-
dial contrast volume of distribution, VDm.
Methods
Patients with systemic AL amyloidosis undergoing rou-
tine work up at the National Amyloidosis Centre were
recruited (n=54, 35 males, 19 females, mean age 64) and
underwent EQ-CMR and conventional CMR including
late enhancement to measure VDm and standard car-
diac work-up including ECG, echocardiography, biomar-
kers (BNP, troponin) and functional assessment (6
minute walk test, 6MWT, where permitted by auto-
nomic neuropathy). Results were compared to normal
controls. Conventional assessment ranked cardiac invol-
vement as definite, probable and none.
Results
VDm was significantly higher in patients than normal
controls (0.25 vs 0.40, P < 0.001). This tracked conven-
tional cardiac assessment (none, probable, definite cor-
responded with a VDm of 0.276 vs 0.342 vs 0.488,
P<0.005), respectively. VDm correlated with cardiac
parameters by echo (e.g. TDI S-wave R2 0.24, P=0.001)
and conventional CMR (e.g. indexed LV mass R2 0.31,
P<0.001). Significant correlations were also seen with
BNP (R2 0.2, P<0.005) and Trop T (R2 0.26, P<0.01).
VDm was associated with ECG abnormalities and
tracked small QRS voltages (R2 0.43, P<0.001). A higher
VDm trended towards a lower 6-minute walk test out-
come (R2 0.1, P=0.09)
Conclusions
The measurement of the myocardial interstitial com-
partment (VDm) using EQ-CMR in systemic AL amyloi-
dosis has the potential to be the first quantitative test
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Figure 1 showing the mean myocardial volume of distributions (and 95% confidence intervals) for normals and patients with systemic AL
amyloidosis (P<0.001).
Figure 2 compares the mean VDm between normals (group 1) and Systemic AL Amyloidosis patients with : No suspected cardiac involvement
(group 2, P=0.44), possible cardiac involvement (group 3, P<0.001) and definite cardiac involvement (group 4, P<0.001).
Banypersad et al. Journal of Cardiovascular Magnetic Resonance 2012, 14(Suppl 1):P174
http://www.jcmr-online.com/content/14/S1/P174
Page 2 of 2
